Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia

por Degryse, S, de Bock, C E, Demeyer, S, Govaerts, I, Bornschein, S, Verbeke, D, Jacobs, K, Binos, S, Skerrett-Byrne, D A, Murray, H C, Verrills, N M, Van Vlierberghe, P, Cools, J, Dun, M D
Publicado 2018

Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia

por Degryse, S., de Bock, C. E., Demeyer, S., Govaerts, I., Bornschein, S., Verbeke, D., Jacobs, K., Binos, S., Skerrett-Byrne, D. A., Murray, H. C., Verrills, N. M., Van Vlierberghe, P., Cools, J., Dun, M. D.
Publicado 2018